financetom
Business
financetom
/
Business
/
Wayfair's Q2 Adjusted Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wayfair's Q2 Adjusted Earnings, Revenue Rise
Aug 4, 2025 4:34 AM

07:12 AM EDT, 08/04/2025 (MT Newswires) -- Wayfair ( W ) reported Q2 adjusted earnings Monday of $0.87 per diluted share, up from $0.47 a year earlier.

Analysts polled by FactSet expected $0.33.

Revenue for the quarter ended June 30 was $3.27 billion, up from $3.12 billion a year earlier.

Analysts polled by FactSet expected $3.13 billion.

Shares of the company rose more than 8% in recent premarket activity Monday.

Price: 71.02, Change: +5.80, Percent Change: +8.89

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CN Rail Flags Capacity Constraints in 2024-2025 Canadian Grain Plan, Notes RBC
CN Rail Flags Capacity Constraints in 2024-2025 Canadian Grain Plan, Notes RBC
Aug 7, 2024
11:17 AM EDT, 08/07/2024 (MT Newswires) -- CN Rail flagged capacity constraints in its 2024-2025 Canadian Grain Plan, notes RBC. The company last week released its 2024-2025 Grain Plan, highlighting capacity risk throughout its report. CN pointed to 1) federal labour regulations that it believes results in +15% more people to move the same amount of freight; 2) extended interswitching;...
Actuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Actuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Aug 7, 2024
Actuate Therapeutics, Inc (NASDAQ:ACTU) IPO will take place August, 08 on the NASDAQ exchange under the ticker ACTU. The company is offering shares at an expected price between $8.00 and $10.00 per share with an insider lock-up period of 180 days ending on February 04, 2025. See also: Benzinga IPO Calendar About Actuate Therapeutics, Inc Actuate Therapeutics, Inc is a...
Medtronic Gets FDA Approval of Simplera CGM; Collaborates With Abbott
Medtronic Gets FDA Approval of Simplera CGM; Collaborates With Abbott
Aug 7, 2024
11:22 AM EDT, 08/07/2024 (MT Newswires) -- Medtronic ( MDT ) said Wednesday it received approval from the US Food and Drug Administration for its disposable Simplera continuous glucose monitor that's half the size of its previous CGMs. The design simplifies the insertion and wear experience, eliminating the need for overtape, the company said. Medtronic ( MDT ) also said...
--Hyatt Nearing Sale of Orlando Property to Ares JV for Around $1 Billion, Bloomberg Reports
--Hyatt Nearing Sale of Orlando Property to Ares JV for Around $1 Billion, Bloomberg Reports
Aug 7, 2024
11:17 AM EDT, 08/07/2024 (MT Newswires) -- Price: 130.40, Change: -1.62, Percent Change: -1.23 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved